A comprehensive view of Sanofi SA. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Sanofi launches new NextGen scholarship program to boost diversity in healthcare; global initiative to help with tuition, living expenses for 100 students at higher education institutions around the world
Published: January 23, 2023 by FiercePharma
J&J cuts COVID-19 vaccine production due to low demand, terminates manufacturing agreements with Catalent, Sanofi
Published: January 16, 2023 by CE NAFTA 2.0 Newswire (Mexico)
California sues Eli Lilly, Novo Nordisk, Sanofi, CVS Caremark, Express Scripts, Optum Rx for driving up insulin cost; lawsuit alleges insulin makers & pharmacy benefit management firms have leveraged their market power to overcharge diabetes patients
Published: January 13, 2023 by Forbes
FDA to review BLA for AstraZeneca and Sanofi’s nirsevimab RSV antibody; single-dose, long-acting antibody targeted for use in newborns, infants in their first FSV season, vulnerable children up to 24 months in second RSV season
Published: January 05, 2023 by Outsourcing-Pharma.com
UK regulators authorize Sanofi's SARS-CoV-2 spike protein vaccine for prevention of COVID-19 disease in adults aged 18 and older; product is indicated as a booster for individuals previously vaccinated
Published: December 21, 2022 by U.S. Regulated Equity Markets (Alternative Disclosure) via PUBT

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count